Instruction for use: Ferrovir

Dosage form: Solution for intramuscular injection

Active substance: Natrii desoxyribonucleas

ATX

J05AX Other antivirals

Pharmacological groups:

Immunomodulating and antiviral agent [Other immunomodulators]

Immunomodulatory and antiviral agents [Antiviral (except HIV) agents]

The nosological classification (ICD-10)

A84 Tick-borne viral encephalitis: Tick-borne encephalitis; Tick-borne encephalitis

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B00.9 Herpetic infection, unspecified: Herpes face; Herpes mucous membranes; Herpes-viral infections; Herpes-viral infections of various localizations; Herpetic infection; Herpetic infections; Herpetic lesions; Latent herpetic infection; Neonatal herpes; Recurrent herpetic infection; Chronic recurrent herpesvirus infection; Chronic recurrent herpetic infection; Acute herpetic disease of the mucous membranes; Recurrent herpes

B07 Viral Warts: Warts; Human Wart Virus; Vulgar warts; Flat wart; Flat and vulgar wart in children; Plantar wart; Common wart; Common plantar wart; Skin Papillomas

B17.1 Acute hepatitis C: Viral active hepatitis C; Viral hepatitis C; Hepatitis C

B18.2 Chronic viral hepatitis C: Hepatitis C; Recurrence of chronic hepatitis C; Chronic active hepatitis C; Chronic viral hepatitis C; Chronic hepatitis C without cirrhosis; Chronic hepatitis C with compensated cirrhosis; Chronic hepatitis C

B20 Disease caused by the human immunodeficiency virus [HIV], manifested as infectious and parasitic diseases

B20-B24 Disease caused by human immunodeficiency virus [HIV]: Deployed stage of HIV infection; AIDS in children; HIV / AIDS infection; Infections with HIV; AIDS; Human Immunodeficiency Virus HIV-1; HIV-1 infection; HIV infection; HIV

B20.3 HIV disease, with manifestations of other viral infections

B25 Cytomegalovirus: Generalized CMV infection in patients with AIDS; Cytomegalovirus infection in patients with impaired immunity; Cytomegalovirus infection; Cytomegalovirus infection in patients with habitual miscarriage Cytomegalovirus retinitis; Cytomegalovirus retinitis in AIDS patients; CMV; CMV in AIDS patients; CMV infection; CMV infection in the presence of immunodeficiency; CMV infection in cancer patients with immunosuppression; CMV-pneumonia; CMV retinitis in patients with weakened immunity; CMV retinitis in AIDS patients

B97.7 Papillomavirus: Human papillomavirus; Asymptomatic selection of human papillomavirus; Papillomavirus infection; The papilloma virus; Upper respiratory tract papillomatosis; Papillomovirus infection; Human papillomaviruses

Composition

Solution for intramuscular injection 1 ml

Active substances: Sodium deoxyribonucleate 15 mg

Iron oxide chloride 0.048 mg

Excipient: water for injection - up to 1 ml

Description of dosage form

Transparent liquid of yellow color without foreign inclusions.

Pharmachologic effect

Mode of action - antiviral, immunomodulating.

Pharmacodynamics

Activates antiviral, antifungal and antimicrobial immunity. It shows antiviral action against RNA and DNA-containing viruses.

Course use (within 14 days) in the treatment of AIDS / HIV infection increases the level of CD4 + lymphocytes in the blood. This increase continues for 1-1,5 months after the end of the course of treatment. At the same time, the viral load in the body decreases, which is expressed in a decrease in the concentration of HIV RNA in comparison with the baseline level.

With recurrent herpesvirus infection, the duration of relapse is reduced and long-term remission follows after a 10-day course of treatment.

In the complex treatment of patients with chronic hepatitis C, it improves the tolerability of treatment (reducing dizziness, nausea, etc.), reducing the replicative activity of the HCV virus of all genotypes, and translating the process into a latent phase with recovery of liver cells and inhibition of viral replication. It is active in the presence of viruses of basic and opportunistic diseases. There is evidence of positive therapy with the drug Ferrovir ® diseases caused by the human papillomavirus and the Epstein-Barr virus.

Pharmacokinetics

With the IM introduction is rapidly absorbed and distributed in organs and tissues with the participation of the endolymphatic pathway of transport; Has a high tropism to the organs of the hematopoietic system; Takes an active part in cellular metabolism, integrating into cellular structures. In the course of daily course use has the property of cumulating in organs and tissues. The time to reach Cmax is 0.5 h (then the concentration of the drug in the blood begins to decrease, due to its distribution in the organs and tissues). T1 / 2 - 36 hours. With repeated administration (every 24 hours for 4 days), there is accumulation of the drug in the spleen, lymph nodes and bone marrow (after the fifth injection the concentration of the drug in all organs and tissues does not increase, its gradual decrease is observed). It is excreted from the body in the form of metabolites, mainly with urine and partly with feces. The average retention time in organs and tissues is 72 hours.

Indication of the Ferrovir

Herpesvirus infection of various localizations, caused by the herpes simplex virus of the 1st and 2nd types, incl. Generalized in immunocompetent persons;

Chronic recurrent genital herpes;

Papillomavirus infection, treatment of pathological conditions (condylomata, warts, dysplasia) caused by the human papillomavirus;

Etiopathogenetic therapy of cervical dysplasia (CIN I, CIN II) associated with human papillomavirus HPV;

Cytomegalovirus infection;

Hepatitis C;

Tick-borne encephalitis;

In combination therapy of HIV-infected patients and AIDS patients, HIV-infected patients with hepatitis C, HIV-infected patients with recurrent herpetic infection.

Contraindications

Individual intolerance;

pregnancy;

Lactation period;

childhood.

Side effects

Perhaps a short-term increase in body temperature (up to 38 ° C), hyperemia and moderate soreness at the injection site.

Interaction

Moderately potentiates the effect of anticoagulants.

In complex therapy reduces the toxicity and negative effects of the drugs (antibacterial, antiviral, antifungal and cytotoxic drugs) in connection with cytoprotective properties and optimization of metabolic processes in hepatocytes.

Dosing and Administration

IM, adults.

Herpesvirus infection - 5 ml (15 mg / ml) solution for the IM introduction (75 mg in terms of dry matter) twice a day (150 mg) for 10 days. According to recent clinical studies, the effectiveness of the same course was proven with a single daily injection of the drug 5 ml (75 mg / day) once a day at intervals of 24 hours, the course - 10 injections.

With chronic recurrent genital herpes, cytomegalovirus infection, the drug is prescribed 5 ml (15 mg / ml) of the solution for IM injection twice a day for 10-15 days.

Complex therapy of combined herpesvirus and papillomavirus infection of the genitals - 5 ml (15 mg / ml) solution for intravenous injection once a day at intervals of 24 hours, the course - 10 injections.

Papillomavirus infection - 5 ml (15 mg / ml) solution for the IM administration once a day at intervals of 48 h, the course - 10 days. For cervical dysplasia (CIN I, CIN II) associated with the HPV human papillomavirus, 5 ml (15 mg / ml) of the IM injection solution are administered once a day at intervals of 48 hours, the course is 10 injections.

Cytomegalovirus infection - 5 ml (15 mg / ml) of the solution for the IM administration 2 times a day for 10 days daily.

Hepatitis C - 5 ml (15 mg / ml) solution for the IM administration 2 times a day for 14 days. In the next 14 days, the drug is administered at the same daily dose every other day. IM, slowly, for 1-2 min.

HIV infection or AIDS - 5 ml (15 mg / ml) of the solution for the IM administration twice a day (150 mg) for 14 days. If necessary - a second course of therapy after 1-1,5 months.

Tick-borne encephalitis - 5 ml (15 mg / ml) solution for the IM administration 2 times a day for 5-10 days.

Overdose

There were no negative effects from an overdose.

Special instructions

To reduce soreness, Ferrovir® is administered intramuscularly, slowly, for 1.5-2 minutes, beforehand by warming the vial in the hand to the body temperature (it is possible in a container with warm water). When warming, the side effects of the drug are reduced. The solution for injections should be fully used immediately after opening the vial, the storage of open vials is not allowed.

IV the introduction of the drug is not allowed!

Information about the possible effect of the drug on the ability to drive vehicles, mechanisms. The effect of the drug on the ability to drive vehicles or moving mechanisms is not noted.

Release form

Solution for the IM introduction, 15 mg / ml. In bottles of colorless or brown glass, ukuporennyh rubber stoppers and rinsed aluminum caps with detachable plastic nozzles, 2 or 5 ml. In the pallets-blister 5 fl. On 5 ml or 10 fl. 2 ml each. In a pack of cardboard 1 pallet-blister.

Manufacturer

CJSC "FI" Technomedservice ". Moscow

Conditions of supply of pharmacies

On prescription.

Storage conditions of the drug Ferrovir

In the dark place at a temperature of 4-20 ° C.

Keep out of the reach of children.

Shelf life of the drug Ferrovir

5 years.

Do not use after the expiry date printed on the package.